Metastatic Left Colon and Rectal Cancer Treatment With Anti_EGFR Targeted Therapy

Metastatic Colorectal Adenocarcinoma Clinical Trial

— EGFR  

Official title:

Retrospective Study of Metastatic Left Colon and Rectal Cancer as Regard Treatment With Anti_EGFR Targeted Therapy

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT06083974
• Other study ID #: Anti_EGFR -Targeted therapy
• Status: Completed
• Start date: January 1, 2015
• Est. completion date: December 30, 2022

Study information

• Verified date: October 2023
• Source: Assiut University
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

Colorectal cancer ranks the second lethal cancer and third prevalent malignant tumour worldwide, Despite of different odern modalities for diagnosis,large number of cases diagnosed at metastatic advanced stage .

New treatment approach has been discovered habe been discovered making a huge revolution in metastatic colorectal cancer represented by targeted therapy including anti_EGFR ,anti_angiogenic and kinase inhibitors .

Description:

Retrospective study aims to evaluate the effect of EGFR expression in metastatic colorectal cancer and the outcome of treatment with anti_EGFR targeted therapy between left colon and rectal cancer

Recruitment information / eligibility

• Status: Completed
• Enrollment: 100
• Est. completion date: December 30, 2022
• Est. primary completion date: December 30, 2022
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 75 Years

Eligibility

Inclusion Criteria:

1. age above 18

2. Both sex

3. Performance status zero to one according to ECOG scale system

4. Histo-pathologial diagnosis adenocarcinoma of left colon or rectum.

5. Patients diagnosed with left colon and rectal cancer.

6. Patients eligible to receive chemotherapy (with renal and liver chemistry, and normal CBC.

7. Patients diagnosed with metastatic stage.

8. K-RAS wild type.

Exclusion Criteria:

1. Second malignancy

2. Histo-pathological types other than adenocarcinoma.

3. Right colon cancer patients.

4. Patients refused receiving anti_EGFR targeted therapy.

5. Patients with any abnormalities preventing to receive chemotherapy.

6. Early stages of colorectal cancer.

7. K-RAS mutant type.

Related Conditions & MeSH terms

• Adenocarcinoma
• Metastatic Colorectal Adenocarcinoma
• Rectal Neoplasms

Locations

Country	Name	City	State
n/a

Sponsors (1)

Lead Sponsor	Collaborator
Assiut University

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	OS and DFS of patients with metastatic colorectal cancer patients received anti_EGFR targeted therapy	Evaluation of anti-EGFR targeted therapy on metastatic cancer rectum and left colon and factors affecting response to treatment	Anti_EGFR targeted therapy in assuit university hospitals from 2015 to 2022
Secondary	Response rate (RR) in patients received chemotherapy only or with combination with targeted therapy.	Factors affecting response to targeted therapy	The response of patients to EGFR targeted therapy in AUH at period from 2015 to 2022

External Links

•   Advances and new perspectives in the treatment of metastatic colon cancer
•   Efficacy and safety of bevacizumab plus chemotherapy in Chinese patients with metastatic colorectal cancer: a randomized phase III ARTIST trial
•   FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer-subgroup analysis of patients with KRAS: mutated tumours in the randomised German AIO study KRK-0306
•   Panitumumab-FOLFOX4 treatment and RAS mutations in colorectal cance
•   The biology of VEGF and its receptor
•   tion between tumour response to first-line chemotherapy and survival in advanced colorectal cancer: a meta-analysis. Meta-Analysis Group in Cancer